









Markets
/
Stocks
/
nasdaq-amrn
/

Amarin Corporation PLC

AMRN

14.920USD

+0.320+2.19%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

309.89MMarket Cap

LossP/E TTM



Amarin Corporation PLC

14.920

+0.320+2.19%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Sell. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

167 / 507

Overall Ranking

301 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Sell

Current Rating

11.000

Target Price

-26.32%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Overvalued

The company’s latest PE is -2.69, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.85M shares, decreasing 28.83% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 8.25, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 72.74M, representing a year-over-year increase of 7.78%, while its net profit experienced a year-over-year increase of 1028.98%.

Score

Industry at a Glance

Previous score

8.30

Change

-0.05



Financials

7.82

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.72

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.69, which is 3684.76% below the recent high of -101.94 and -4995.83% above the recent low of -137.25.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 167/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 4.67, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Amarin Corporation PLC is 11.00, with a high of 12.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

4.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Sell

Current Rating

11.000

Target Price

-24.66%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Amarin Corporation PLC

AMRN

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 4.84, which is lower than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 15.65 and the support level at 14.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.81

Change

0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.090

Sell

RSI(14)

46.367

Neutral

STOCH(KDJ)(9,3,3)

31.121

Neutral

ATR(14)

0.472

Low Volatility

CCI(14)

-67.470

Neutral

Williams %R

68.067

Sell

TRIX(12,20)

-0.142

Sell

StochRSI(14)

99.893

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

14.878

Buy

MA10

14.968

Sell

MA20

15.179

Sell

MA50

15.355

Sell

MA100

13.980

Buy

MA200

12.046

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 18.61%, representing a quarter-over-quarter decrease of 7.95%. The largest institutional shareholder is PRFDX, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Sarissa Capital Management, L.P.

1.24M

Kynam Capital Management LP

620.73K

Acadian Asset Management LLC

189.58K

+112.31%

Eversept Partners, LP

169.96K

+124.13%

Morgan Stanley & Co. LLC

116.05K

-42.96%

SCP Investment, LP

125.00K

WaterFront Wealth, Inc.

125.73K

+1.32%

Longitude (Cayman) Ltd

81.00K

-31.65%

Berg (Aaron D.)

80.71K

+83.12%

Two Sigma Investments, LP

162.85K

-16.99%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 4.69, which is higher than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.61. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.